GZ 402666

Drug Profile

GZ 402666

Alternative Names: 2nd generation aglucosidase-alpha; GZ-402666; neo rhGAA; Neo-recombinant human acid alpha-glucosidase; Neo-rhGAA; Neo-rhGAA enzyme therapy; NeoGAA

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glycogen storage disease type II

Most Recent Events

  • 29 Sep 2017 Genzyme initiates enrolment in the Mini-COMET trial for Glycogen storage disease type II (In adolescents, In adults, In children, In the elderly) in France and United Kingdom (NCT03019406)
  • 10 Jan 2017 Genzyme plans the phase II Mini-COMET trial for Glycogen storage disease type II (In adolescents, In children, In infants, Treatment-experienced) in USA (IV, Infusion) (NCT03019406)
  • 01 Oct 2016 Phase-III clinical trials in Glycogen storage disease type II (In children, In adolescents, In adults, In the elderly) in USA, Belgium, Denmark, France, Netherlands, United Kingdom, Sweden (IV) (NCT02782741)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top